Angiolab, Inc. (XKON:251280)

Angiolab Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2015	FY 2014
Period Ending	Dec 31, 2015	Dec 31, 2014
Revenue	702.62	878.44
Revenue Growth (YoY)	-20.02%	-
Cost of Revenue	364.03	482.43
Gross Profit	338.6	396.01
Selling, General & Admin	528.36	402.34
Research & Development	277.19	189.44
Other Operating Expenses	17.33	12.82
Operating Expenses	1,055	772.36
Operating Income	-716.07	-376.36
Interest Expense	-0.92	-19.78
Interest & Investment Income	63.5	15.2
Currency Exchange Gain (Loss)	15.43	18.62
Other Non Operating Income (Expenses)	-21.48	0.79
EBT Excluding Unusual Items	-659.54	-361.52
Asset Writedown	-526.96	-
Other Unusual Items	-	11.21
Pretax Income	-1,187	-350.31
Net Income	-1,187	-350.31
Net Income to Common	-1,187	-350.31
Shares Outstanding (Basic)	1	1
Shares Outstanding (Diluted)	1	1
Shares Change (YoY)	-0.09%	-
EPS (Basic)	-1356.00	-400.00
EPS (Diluted)	-1356.00	-400.00
Free Cash Flow	-105.3	-182.39
Free Cash Flow Per Share	-120.34	-208.26
Gross Margin	48.19%	45.08%
Operating Margin	-101.91%	-42.84%
Profit Margin	-168.87%	-39.88%
Free Cash Flow Margin	-14.99%	-20.76%
EBITDA	-483.63	-224.34
EBITDA Margin	-68.83%	-25.54%
D&A For EBITDA	232.44	152.02
EBIT	-716.07	-376.36
EBIT Margin	-101.91%	-42.84%
Advertising Expenses	6.08	0.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.